REGULATED INFORMATION COMBINED SHAREHOLDERS’ MEETING OF IPSEN S.A.HELD ON 31 MAY 2023 ALL THE RESOLUTIONS SUBMITTED TO THE SHAREHOLDERS’ VOTE HAVE BEEN APPROVED Paris , 31 May. | May 31, 2023
Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva , an ultra-rare disease with an estimated prevalence of 1.36 per million. | May 26, 2023
Six abstracts to be presented demonstrating efficacy and tolerability of investigational Bylvay in select cholestatic liver diseasesNew data emphasizes the consistent benefit of Bylvay as an. | May 17, 2023
INFORMATION RELATING TO THE HOLDING OF THE COMBINED SHAREHOLDERS’ MEETING OF 31 MAY 2023 FORMALITIES FOR MAKING AVAILABLE AND CONSULTINGPREPARATORY DOCUMENTS TO THE MEETING . | May 10, 2023